Home
Kobo Biotech Ltd PE Ratio

Kobo Biotech Ltd
NSE: KOBOBIOTECH
PE
Key Highlights
- The P/E Ratio of Kobo Biotech Ltd is 0 as of 22 Feb 12:02 PM .
- The P/E Ratio of Kobo Biotech Ltd changed from 0 on March 2020 to 0 on March 2023 . This represents a CAGR of 0.0% over 4 years.
- The Latest Trading Price of Kobo Biotech Ltd is ₹ 2.77 as of 21 Feb 15:30 .
- The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
- The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.
Historical P/E Ratio of Kobo Biotech Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of Kobo Biotech Ltd
Company Fundamentals for Kobo Biotech Ltd

Kobo Biotech Ltd
NSE: KOBOBIOTECH
Share Price
Market Price of Kobo Biotech Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
21 Feb 2025 | 2.77 |
20 Feb 2025 | 2.64 |
19 Feb 2025 | 2.75 |
18 Feb 2025 | 2.85 |
17 Feb 2025 | 2.83 |
14 Feb 2025 | 2.71 |
13 Feb 2025 | 2.78 |
12 Feb 2025 | 2.9 |
11 Feb 2025 | 2.89 |
10 Feb 2025 | 2.98 |
SWOT Analysis Of Kobo Biotech Ltd
BlinkX Score for Kobo Biotech Ltd
Asset Value vs Market Value of Kobo Biotech Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of P/E Ratio
Company | Market Cap | PE Ratio |
---|
Kobo Biotech Ltd | 6.6 | - |
Sun Pharmaceuticals Industries Ltd | 394223 | 33.4 |
Divis Laboratories Ltd | 152610 | 73.8 |
Cipla Ltd | 119067 | 23.9 |
Torrent Pharmaceuticals Ltd | 102739 | 55.2 |
Dr Reddys Laboratories Ltd | 96124 | 17.9 |
Company | |
---|---|
Kobo Biotech Ltd | 6.6 |
Sun Pharmaceuticals Industries Ltd | 394223 |
Divis Laboratories Ltd | 152610 |
Cipla Ltd | 119067 |
Torrent Pharmaceuticals Ltd | 102739 |
Dr Reddys Laboratories Ltd | 96124 |
PE Ratio of Kobo Biotech Ltd Explained
₹6.6
Market cap
₹-5
Earnings
0.0X
PE Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E Ratio Formula
P/E ratio = (CMP of share/ Earning per share)
Types of Price to Earning Ratio
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
PE Ratio of Pharmaceuticals Industry over time
PE Ratio of Top Sectors
Historical Market Cap of Kobo Biotech Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Kobo Biotech Ltd
Historical Revenue, EBITDA and Net Profit of Kobo Biotech Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Revenue, EBITDA and Net Profit of Kobo Biotech Ltd
Revenue
EBITDA
Net Profit
Historical Dividend Payout of Kobo Biotech Ltd
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Historical Dividend Payout of Kobo Biotech Ltd
About Kobo Biotech Ltd
- Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992.
- Effective 19th October, 2020, the Company's name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited.
- The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US.
Kobo Biotech Ltd News Hub
Kobo Biotech reports standalone net loss of Rs 1.33 crore in the June 2024 quarter
Net Loss of Kobo Biotech reported to Rs 1.33 crore in the quarter ended June 2024 as against net los
Read more
14 Aug 24
Kobo Biotech to discuss results
Kobo Biotech will hold a meeting of the Board of Directors of the Company on 14 August 2024. Powered
Read more
13 Aug 24